(Q35026014)

5 August 2017

1 reference

title

Monoclonal antibodies in immune and inflammatory diseases (English)

1 reference

5 August 2017

Evangelos Andreakos

1

1 reference

5 August 2017

Peter C Taylor

series ordinal

2

1 reference

5 August 2017

Marc Feldmann

series ordinal

3

1 reference

5 August 2017

language of work or name

1 reference

1 December 2002

1 reference

Current Opinion in Biotechnology

5 August 2017

1 reference

5 August 2017

13

1 reference

5 August 2017

6

1 reference

5 August 2017

615-620

1 reference

Cytokines and anti-cytokine biologicals in autoimmunity: present and future

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Development of anti-TNF therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Intra-articular primatised anti-CD4: efficacy in resistant rheumatoid knees. A study of combined arthroscopy, magnetic resonance imaging, and histology

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Etanercept therapy in children with treatment-resistant uveitis

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900355-5

7 January 2021

10.1016/S0958-1669(02)00355-5

Identifiers

DOI

1 reference

5 August 2017

1 reference